Global /South Korea /Healthcare /Drug Manufacturers - General /475830

Orum Therapeutics, Inc.

475830

• KRX: 475830 • Delayed

88,200KRW -1.5%

57.54 USD

As of 5 June 2026, Orum Therapeutics, Inc. has a market cap of $1.24B USD, ranking #9524 globally and #259 in South Korea. It ranks #823 in the Healthcare sector, and #311 in the Drug Manufacturers - General industry.

Global Rank

9524

Country Rank

259

Sector Rank

823

Industry Rank

311

Key Stats

Market Cap

$1.24BUSD

1.9T KRW

Enterprise Value

$1.17BUSD

1.79T KRW

Revenue (TTM)

$15.37KUSD

23.56M KRW

EBITDA (TTM)

-$31.62MUSD

-48.46B KRW

Net Income (TTM)

-$27.38MUSD

-41.97B KRW

PS Ratio

80643.3

PB Ratio

14.5

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Sung-Joo Lee open_in_new

Founded

2016

Website

orumrx.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-1.5%	10%	-20%	-24%	109%	-25%	401%	200%	200%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	475830 ISIN: KR7475830006 Shares Out.: Shares Outstanding: 21.513M¹ Shares Float: 13.725M² TV: TradingView: KRX: 475830 SA: Stock Analysis: KRX: 475830 YF: Yahoo Finance: 475830.KS GF: Google Finance: KRX: 475830 BA: Barron's: 475830 MS: Morningstar: XKRX: 475830	88,200 KRW	TV: TradingView: KRX: 475830 SA: Stock Analysis: KRX: 475830 YF: Yahoo Finance: 475830.KS GF: Google Finance: KRX: 475830 BA: Barron's: 475830 MS: Morningstar: XKRX: 475830

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Orum Therapeutics, Inc.

Orum Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of pharmaceuticals for cancer and immune diseases. The company develops BMS-986497 (ORM-6151), which is in phase 1 clinical trial to treat acuta myeloid leukemia and high-risk myelodysplastic syndromes; ORM-1153, which is in preclinical trial to treat acuta myeloid leukemia and heme-onc; and ORM-1023, which is in preclinical trial for the treatment of small cell lung cancer and neuroendocrine tumor. It also develops multiple programs; and E3 Ligase-DAC adaptor. The company was founded in 2016 and is headquartered in Daejeon, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.07B 13.91T KRW 632%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.72B 10.3T KRW 442%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.2B 7.97T KRW 320%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$4.92B 7.55T KRW 297%	-	South Korea
Yuhan Corp. KRX: 000100	$4.51B 6.92T KRW 264%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.41B 6.76T KRW 256%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 61K%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 44K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 29K%	97.4	United States
Roche Holding AG SIX: RO	$323.4B 256.25B CHF 26K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.25B 215.59B GBP 23K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$276.26B 218.9B CHF 22K%	20.5	Switzerland

chevron_leftBack